JP2020536887A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020536887A5 JP2020536887A5 JP2020520007A JP2020520007A JP2020536887A5 JP 2020536887 A5 JP2020536887 A5 JP 2020536887A5 JP 2020520007 A JP2020520007 A JP 2020520007A JP 2020520007 A JP2020520007 A JP 2020520007A JP 2020536887 A5 JP2020536887 A5 JP 2020536887A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- composition according
- patient
- ddr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 claims description 142
- 206010028980 Neoplasm Diseases 0.000 claims description 91
- 201000011510 cancer Diseases 0.000 claims description 77
- 230000028617 response to DNA damage stimulus Effects 0.000 claims description 61
- 238000011282 treatment Methods 0.000 claims description 39
- 108090000623 proteins and genes Proteins 0.000 claims description 38
- 239000012661 PARP inhibitor Substances 0.000 claims description 34
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 claims description 34
- 230000002950 deficient Effects 0.000 claims description 31
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 28
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 28
- 239000005557 antagonist Substances 0.000 claims description 28
- 108700020463 BRCA1 Proteins 0.000 claims description 26
- 102000036365 BRCA1 Human genes 0.000 claims description 26
- 101150072950 BRCA1 gene Proteins 0.000 claims description 26
- 108700020462 BRCA2 Proteins 0.000 claims description 26
- 102000052609 BRCA2 Human genes 0.000 claims description 26
- 101150008921 Brca2 gene Proteins 0.000 claims description 26
- 238000003556 assay Methods 0.000 claims description 26
- 102000000872 ATM Human genes 0.000 claims description 18
- 108010004586 Ataxia Telangiectasia Mutated Proteins Proteins 0.000 claims description 18
- 229950002916 avelumab Drugs 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 14
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 12
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 12
- 206010033128 Ovarian cancer Diseases 0.000 claims description 10
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 10
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 9
- 206010060862 Prostate cancer Diseases 0.000 claims description 8
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 8
- 235000003332 Ilex aquifolium Nutrition 0.000 claims description 7
- 235000002296 Ilex sandwicensis Nutrition 0.000 claims description 7
- 235000002294 Ilex volkensiana Nutrition 0.000 claims description 7
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 6
- 230000007812 deficiency Effects 0.000 claims description 6
- 239000012458 free base Substances 0.000 claims description 6
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 6
- 208000027706 hormone receptor-positive breast cancer Diseases 0.000 claims description 5
- 206010044412 transitional cell carcinoma Diseases 0.000 claims description 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 3
- 230000007547 defect Effects 0.000 claims description 3
- 210000004602 germ cell Anatomy 0.000 claims description 3
- 230000006801 homologous recombination Effects 0.000 claims description 3
- 238000002744 homologous recombination Methods 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- 230000000392 somatic effect Effects 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 description 15
- 238000011269 treatment regimen Methods 0.000 description 15
- 238000011518 platinum-based chemotherapy Methods 0.000 description 13
- 230000001394 metastastic effect Effects 0.000 description 11
- 206010061289 metastatic neoplasm Diseases 0.000 description 11
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 8
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 7
- 229960004562 carboplatin Drugs 0.000 description 7
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 229930012538 Paclitaxel Natural products 0.000 description 5
- 229940123237 Taxane Drugs 0.000 description 5
- 229960001592 paclitaxel Drugs 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 5
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 5
- 230000000973 chemotherapeutic effect Effects 0.000 description 4
- 229910052697 platinum Inorganic materials 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 229940124060 PD-1 antagonist Drugs 0.000 description 3
- 229960005277 gemcitabine Drugs 0.000 description 3
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 3
- 238000001794 hormone therapy Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 2
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 2
- 201000001342 Fallopian tube cancer Diseases 0.000 description 2
- 208000013452 Fallopian tube neoplasm Diseases 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- 208000026149 Primary peritoneal carcinoma Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229940045799 anthracyclines and related substance Drugs 0.000 description 2
- 238000011319 anticancer therapy Methods 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229960004117 capecitabine Drugs 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 229960003668 docetaxel Drugs 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 210000003101 oviduct Anatomy 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- 229960002066 vinorelbine Drugs 0.000 description 2
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 101100091501 Mus musculus Ros1 gene Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 229960001573 cabazitaxel Drugs 0.000 description 1
- BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- HWGQMRYQVZSGDQ-HZPDHXFCSA-N chembl3137320 Chemical compound CN1N=CN=C1[C@H]([C@H](N1)C=2C=CC(F)=CC=2)C2=NNC(=O)C3=C2C1=CC(F)=C3 HWGQMRYQVZSGDQ-HZPDHXFCSA-N 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 229960004671 enzalutamide Drugs 0.000 description 1
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 description 1
- 230000004547 gene signature Effects 0.000 description 1
- 229950004550 talazoparib Drugs 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 208000023747 urothelial carcinoma Diseases 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762572024P | 2017-10-13 | 2017-10-13 | |
| US62/572,024 | 2017-10-13 | ||
| US201862697587P | 2018-07-13 | 2018-07-13 | |
| US62/697,587 | 2018-07-13 | ||
| PCT/US2018/055174 WO2019075032A1 (en) | 2017-10-13 | 2018-10-10 | COMBINATION OF A PARP INHIBITOR AND A PD-1 AXIS BINDING ANTAGONIST |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020536887A JP2020536887A (ja) | 2020-12-17 |
| JP2020536887A5 true JP2020536887A5 (enExample) | 2021-09-02 |
Family
ID=64049735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020520007A Withdrawn JP2020536887A (ja) | 2017-10-13 | 2018-10-10 | Ｐａｒｐ阻害剤およびｐｄ−１系結合アンタゴニストの組合せ |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20200254091A1 (enExample) |
| EP (1) | EP3694551A1 (enExample) |
| JP (1) | JP2020536887A (enExample) |
| KR (1) | KR20200071097A (enExample) |
| CN (1) | CN111225685A (enExample) |
| AU (1) | AU2018347331A1 (enExample) |
| BR (1) | BR112020006371A2 (enExample) |
| CA (1) | CA3078806A1 (enExample) |
| IL (1) | IL273994A (enExample) |
| MX (1) | MX2020003361A (enExample) |
| RU (1) | RU2020113246A (enExample) |
| TW (1) | TW201922288A (enExample) |
| WO (1) | WO2019075032A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190062515A (ko) * | 2016-10-06 | 2019-06-05 | 화이자 인코포레이티드 | 암의 치료를 위한 아벨루맙의 투약 용법 |
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| TWI852940B (zh) * | 2018-09-04 | 2024-08-21 | 美商泰沙羅公司 | 治療癌症之方法 |
| CN113116881B (zh) * | 2019-12-31 | 2025-03-07 | 甫康（上海）健康科技有限责任公司 | 一种用于治疗肿瘤的药物组合及其应用 |
| JP2023524270A (ja) * | 2020-05-04 | 2023-06-09 | メルク・シャープ・アンド・ドーム・エルエルシー | Ｐｄ－１アンタゴニスト、化学放射線療法およびｐａｒｐ阻害剤の組み合わせを用いた癌の治療方法 |
| WO2022200982A1 (en) * | 2021-03-24 | 2022-09-29 | Pfizer Inc. | Combination of talazoparib and an anti-androgen for the treatment of ddr gene mutated metastatic castration-sensitive prostate cancer |
| TWI883565B (zh) | 2022-10-02 | 2025-05-11 | 美商輝瑞大藥廠 | 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合 |
| TW202425976A (zh) | 2022-12-17 | 2024-07-01 | 美商輝瑞大藥廠 | 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合 |
| TW202600137A (zh) | 2024-04-04 | 2026-01-01 | 美商輝瑞股份有限公司 | 於使用ｐａｒｐ抑制劑的治療作為預測性生物標記之ｔｍｐｒｓｓ２－ｅｒｇ和ｒｂｉ及使用ｐａｒｐ抑制劑之治療方法 |
| WO2026078615A1 (en) | 2024-10-09 | 2026-04-16 | Pfizer Inc. | Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer |
| WO2026078619A1 (en) | 2024-10-09 | 2026-04-16 | Pfizer Inc. | Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| CN104478875B (zh) | 2008-08-06 | 2017-04-12 | 麦迪韦逊科技有限公司 | 聚(adp‑核糖)聚合酶(parp)的二氢吡啶并酞嗪酮抑制剂 |
| EP2531033A4 (en) | 2010-02-03 | 2013-07-31 | Biomarin Pharm Inc | POLY (ADP-RIBOSE) POLYMERASE (PARP) DIHYDROPYRIDOPHTHALAZINE HEMMER FOR USE IN THE TREATMENT OF PTEN-LACK ASSOCIATED DISEASES |
| KR101826652B1 (ko) | 2010-02-08 | 2018-02-07 | 메디베이션 테크놀로지즈, 인크. | 디히드로피리도프탈라지논 유도체의 합성 방법 |
| KR20190120458A (ko) | 2010-10-21 | 2019-10-23 | 메디베이션 테크놀로지즈 엘엘씨 | 결정질의 (8s,9r)-5-플루오로-8-(4-플루오로페닐)-9-(1-메틸-1h-1,2,4-트리아졸-5-일)-8,9-디하이드로-2h-피리도[4,3,2-de]프탈라진-3(7h)-온 토실레이트 염 |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| CN105916846A (zh) | 2013-11-07 | 2016-08-31 | 麦迪韦逊科技有限公司 | 用于合成经保护的n-烷基三唑甲醛的三唑中间体 |
| PL3102605T3 (pl) * | 2014-02-04 | 2019-06-28 | Pfizer Inc. | Połączenie antagonisty pd-1 i inhibitora vegfr do leczenia nowotworu |
| EP3563870A1 (en) * | 2014-07-15 | 2019-11-06 | F. Hoffmann-La Roche AG | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |
| EA201790290A1 (ru) | 2014-07-31 | 2017-07-31 | Медивэйшн Текнолоджиз, Инк. | Формерные соли (2s,3s)-метил 7-фтор-2-(4-фторфенил)-3-(1-метил-1h-1,2,4-триазол-5-ил)-4-оксо-1,2,3,4-тетрагидрохинолин-5-карбоксилата и способы их получения |
| CN107206088A (zh) * | 2014-12-05 | 2017-09-26 | 豪夫迈·罗氏有限公司 | 使用pd‑1轴拮抗剂和hpk1拮抗剂用于治疗癌症的方法和组合物 |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| RU2714233C2 (ru) * | 2015-02-26 | 2020-02-13 | Мерк Патент Гмбх | Ингибиторы pd-1 / pd-l1 для лечения рака |
| MX2017015937A (es) * | 2015-06-08 | 2018-12-11 | Genentech Inc | Métodos de tratamiento del cáncer con anticuerpos anti-ox40 y antagonistas de unión al eje de pd-1. |
| SG11201803462PA (en) | 2015-10-26 | 2018-05-30 | Medivation Tech Llc | Treatment of small cell lung cancer with a parp inhibitor |
-
2018
- 2018-10-10 CA CA3078806A patent/CA3078806A1/en not_active Abandoned
- 2018-10-10 JP JP2020520007A patent/JP2020536887A/ja not_active Withdrawn
- 2018-10-10 US US16/754,485 patent/US20200254091A1/en not_active Abandoned
- 2018-10-10 EP EP18795891.3A patent/EP3694551A1/en not_active Withdrawn
- 2018-10-10 WO PCT/US2018/055174 patent/WO2019075032A1/en not_active Ceased
- 2018-10-10 BR BR112020006371-1A patent/BR112020006371A2/pt not_active IP Right Cessation
- 2018-10-10 RU RU2020113246A patent/RU2020113246A/ru unknown
- 2018-10-10 MX MX2020003361A patent/MX2020003361A/es unknown
- 2018-10-10 AU AU2018347331A patent/AU2018347331A1/en not_active Abandoned
- 2018-10-10 KR KR1020207013511A patent/KR20200071097A/ko not_active Withdrawn
- 2018-10-10 CN CN201880066544.4A patent/CN111225685A/zh active Pending
- 2018-10-12 TW TW107135947A patent/TW201922288A/zh unknown
-
2020
- 2020-04-16 IL IL273994A patent/IL273994A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020536887A5 (enExample) | ||
| JP2016501213A5 (enExample) | ||
| JP2023546009A5 (enExample) | ||
| JP2022536854A5 (enExample) | ||
| RU2016151303A (ru) | Применение эрибулина в лечении рака | |
| He et al. | Combined immunotherapy for metastatic triple-negative breast cancer based on PD-1/PD-L1 immune checkpoint blocking | |
| RU2020113246A (ru) | Комбинация ингибитора parp и антагониста, связывающегося с осью pd-1 | |
| Sekine et al. | A randomized phase III study of single-agent amrubicin vs. carboplatin/etoposide in elderly patients with extensive-disease small-cell lung cancer | |
| CA3080644A1 (en) | Use of parp inhibitor in treating chemotherapy-resistant ovarian cancer or breast cancer | |
| Lu et al. | Polymeric micellar paclitaxel (Pm-Pac) prolonged overall survival for NSCLC patients without pleural metastasis | |
| JP2017516802A5 (enExample) | ||
| JP2018513155A5 (enExample) | ||
| Satolli et al. | Gastric cancer: The times they are a-changin’ | |
| RU2019134769A (ru) | Композиции для лечения резистентных к лекарственным средствам опухолей и способы их применения | |
| He et al. | Changing patterns of neoadjuvant therapy for locally advanced rectal cancer: A narrative review | |
| JP2025504278A5 (enExample) | ||
| Ozdemir et al. | Capecitabine/cisplatin doublet in anthracycline and taxane pretreated and HER-2 negative metastatic breast carcinoma patients | |
| JP2023529485A5 (enExample) | ||
| Maqsood et al. | Revolutionizing breast cancer care: cutting-edge breakthroughs and future | |
| Wang et al. | RATIONALE 307: Phase 3 Study of Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small Cell Lung Cancer | |
| Yasenchak et al. | 397 Phase 2 results of XL184 in a cohort of patients (pts) with advanced non-small cell lung cancer (NSCLC) | |
| Modesto et al. | Tolerance and efficacy of dose escalation using IMRT combined with chemotherapy for unresectable esophageal carcinoma: Long-term results of 51 patients | |
| Lin | 178P Targeting mitochondria EGCG nanoparticles synergistically regulate immunogenic cell death and copper death to improve the anti-tumor efficacy of breast cancer | |
| Iovita et al. | 117P Targeted compound screening for the exploration of actionable vulnerabilities in LUSC | |
| Liu et al. | Tislelizumab plus bevacizumab and XELOX as first-line treatment of MSS/pMMR RAS-mutant metastatic colorectal cancer (TACTIC CRC-02): a phase II study |